QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.

Carlos Diaz-ArocutipaAna Brañez-CondorenaAdrian V Hernandez

Published in: Pharmacoepidemiology and drug safety (2021)

COVID-19 patients treated with hydroxychloroquine/chloroquine with or without azithromycin had a relatively high prevalence and risk of QTc prolongation. However, the prevalence of arrhythmic events was very low, probably due to underreporting. The limited information about lopinavir/ritonavir showed that it does not prolong the QTc interval.

Keyphrases

coronavirus disease
sars cov
risk factors
antiretroviral therapy
respiratory syndrome coronavirus
plasmodium falciparum
health information